Jiangsu Vcare Pharmatech Co.,Ltd.

On Chemball

My Chemball

As Supplier

My RFQ Manage Products

As Buyer

My RFQ Post RFQ

My Account

+86-571-8627 3270

Jiangsu Vcare PharmaTech Co.,Ltd.

14 YRS

Jiangsu, China

CNY 50 Million

13320 m²

100-500 people

Main Products: 2-((2,6-Difluorobenzyl)(Ethoxycarbonyl)Amino)-4-((Dimethylamino)Methyl)-5-(4-Nitrophenyl)Thiophene-3-Carboxylic acid

Jiangsu, China

Contact Supplier

Home Company Profile Contact Us Post Buying Request

ABOUT US

Jiangsu Vcare PharmaTech Co., Ltd., located in Nanjing Jiangbei New Area, one of state-level new areas, is a high-tech company providing research and development services for the whole industry chain of chemical drugs. Vcare specializes in R&D, application and domestic/international transfer of generic and innovative drugs and R&D, manufacture and sales of featured pharmaceutical intermediates. Vcare was founded by professors of China Pharmaceutical University and overseas returnees in August 2010. Now Vcare has 350 researchers including 9 doctors and 92 masters. The whole team have many years of industry background and strong technological advantages in chemical synthesis and generic and innovative drug development, and has extensive experience in business management. Vcare has 21,000㎡ comprehensive R&D center located at No. 136, Huakang Road, Jiangbei New Area, Nanjing as well as several cooperative manufacturing bases and is honored as National High-Tech Enterprise, Nanjing Chemical Drug Engineering Technology Research Center, Jiangbei New Area Lingque Enterprise and co-built a provincial graduate workstation with China Pharmaceutical University. Vcare takes the international advanced management mode to operate well-equipped laboratories for synthesis, analysis, formulation, cell and enzyme activity detection and has an experienced clinical audit management team. Vcare can provide clients with "chemical + pharmaceutical + clinical" full-industry chain development services based on well-developed research and development system, quality management system and production conditions. Vcare has formed innovative drug, generic drug and pharmaceutical intermediate pipelines mainly focusing on cardiac-cerebral vascular, tumor and endocrine areas. Up to now, Vcare has applied 5 INDs and 20 ANDAs and assisted clients with obtaining 9 clinical trial approvals and 8 production licenses. Vcare’s IND Vicagrel has successively obtained “Twelfth Five-Year Plan” and “Thirteenth Five-Year Plan” national major support. There are dozens featured generics intermediate projects under manufacturing in Vcare’s cooperative bases. Vcare has accumulatively applied 89 domestic and international patents and 21 patents have been authorized.

Basic Information